The FDA issued warning letters to multiple companies in 2026 after reviewing their websites, inspecting facilities, or identifying other regulatory violations involving peptide-related and drug products. In the cited cases, the FDA identified website claims, product presentation, intended use, manufacturing practices, or other regulatory issues that supported its findings. This article highlights 14 companies that […]
Recent FDA warning letters to peptide companies in 2026 show that products marketed as ‘research use only’ can attract regulatory scrutiny when their labeling, websites, or other marketing materials indicate an intended use in humans. These cases also show that FDA may consider product claims, website content, intended use, and the presentation of injectable products […]
As of September 2026, retatrutide does not have an official commercial release date. Eli Lilly is still developing the drug, although the program has advanced substantially through Phase 3 clinical trials. Retatrutide, also known as LY3437943, remains an investigational medicine developed by Eli Lilly. It is a triple receptor agonist that targets: This combination distinguishes […]
